Evolving Strategies to Ease the Burden Related to the Treatment of nAMD

Program Overview

Neovascular age-related macular degeneration (nAMD) is among the leading causes of blindness worldwide. Central vision loss can progress quickly and a timely diagnosis and treatment plan are crucial for maintaining visual acuity, independence, and quality of life. In this Clinical Reflections® activity, you will be challenged to reflect back on a mismanaged case of nAMD and explore ways the patient could have been better treated. Drs. David Brown and Eric Schneider will lead you through this exercise, demonstrating the benefits and limitations of current treatment options for nAMD and reviewing recent data on novel and emerging therapies.

Credit Expired

Target Audience

Ophthalmology, retina specialists, and optometry clinicians 

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Assess the benefits and limitations of conventional intravitreal therapies and dosing strategies for the management of neovascular age-related macular degeneration (nAMD)
  • Identify the potential implications of recent data on novel and emerging treatment strategies on the management of neovascular age-related macular degeneration (nAMD)

Activity Faculty

David M. Brown, MD, FACS

David M. Brown, MD, FACS

Clinical Professor, Ophthalmology
Cullen Eye Institute, Baylor College of Medicine
Vice Chair, Research
Blanton Eye Institute, Houston Methodist Hospital
Director, Research
Retina Consultants of Texas
San Antonio, TX

78-23-1288-VL-002 AMD-Faculty Headshot-Schneide

Eric W. Schneider, MD, FASRS

Retina Specialist, Ophthalmology Clinic
Tennessee Retina
Nashville, TN

Resources

Subscribe

Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources